Clareo Health | Microbiologic Response With Linezolid And Vancomycin In Ventilator-Associated Pneumonia Due To Methicillin Resistant Staphylococcus Aureus
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
The patient must have or be suspected of having a ventilator-associated pneumonia (VAP) due to MRSA.
Patient must be hospitalized for at least 5 days, must be ventilator-dependent ≥ 48 hours prior to screen/baseline, and anticipated to remain on the ventilator for 72 hours after enrollment so follow-up BAL can be performed.
Clinical picture compatible with pneumonia (acquired during ventilation)
Chest X Ray at baseline/screen or within 24 hours of initiation of therapy must be consistent with diagnosis of pneumonia
You may not be if
Hypersensitivity to linezolid, vancomycin, or one of the excipients in any of these drug formulations.
Infections due to gram-positive organisms known to be resistant to either of the study drugs.
Any antibiotic used in the treatment of MRSA, such as vancomycin, TMP/SMX, rifampin, or linezolid, for more than 48 hours prior to patient's enrollment into the study.
Patients with neutropenia, AIDS, lymphoma or anticipated chemotherapy.
Patients who have long-term tracheostomy (for more than 60 days). Acute tracheostomy patients are allowed.
